AVITA Medical, Inc. (RCEL)
12.72
+0.71
(+5.91%)
USD |
NASDAQ |
Oct 02, 16:00
12.66
-0.06
(-0.51%)
After-Hours: 20:00
AVITA Medical Enterprise Value : 430.73M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 430.73M |
| October 01, 2026 | 408.78M |
| September 30, 2026 | 400.12M |
| September 29, 2026 | 407.23M |
| September 28, 2026 | 398.26M |
| September 25, 2026 | 403.52M |
| September 24, 2026 | 395.48M |
| September 23, 2026 | 375.99M |
| September 22, 2026 | 392.69M |
| September 21, 2026 | 372.59M |
| September 18, 2026 | 378.16M |
| September 17, 2026 | 384.34M |
| September 16, 2026 | 360.53M |
| September 15, 2026 | 353.11M |
| September 14, 2026 | 352.49M |
| September 11, 2026 | 342.90M |
| September 10, 2026 | 342.28M |
| September 09, 2026 | 351.56M |
| September 08, 2026 | 359.29M |
| September 04, 2026 | 383.73M |
| September 03, 2026 | 375.69M |
| September 02, 2026 | 370.12M |
| September 01, 2026 | 348.78M |
| August 31, 2026 | 349.71M |
| August 28, 2026 | 357.44M |
| Date | Value |
|---|---|
| August 27, 2026 | 356.51M |
| August 26, 2026 | 364.86M |
| August 25, 2026 | 362.08M |
| August 24, 2026 | 343.83M |
| August 21, 2026 | 348.47M |
| August 20, 2026 | 349.40M |
| August 19, 2026 | 357.13M |
| August 18, 2026 | 341.98M |
| August 17, 2026 | 281.67M |
| August 14, 2026 | 280.12M |
| August 13, 2026 | 285.07M |
| August 12, 2026 | 288.47M |
| August 11, 2026 | 290.95M |
| August 10, 2026 | 272.39M |
| August 07, 2026 | 277.65M |
| August 06, 2026 | 184.25M |
| August 05, 2026 | 175.59M |
| August 04, 2026 | 180.54M |
| August 03, 2026 | 180.23M |
| July 31, 2026 | 173.42M |
| July 30, 2026 | 176.21M |
| July 29, 2026 | 174.66M |
| July 28, 2026 | 179.92M |
| July 27, 2026 | 184.25M |
| July 24, 2026 | 179.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Halozyme Therapeutics, Inc. | 14.44B |
| Iovance Biotherapeutics, Inc. | 6.187B |
| Amgen, Inc. | 261.20B |
| Editas Medicine, Inc. | 261.86M |
| Arcus Biosciences, Inc. | 2.516B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.663M |
| Revenue (Quarterly) | 21.70M |
| Total Expenses (Quarterly) | 29.36M |
| EPS Diluted (Quarterly) | -0.2492 |
| Gross Profit Margin (Quarterly) | 81.87% |
| Profit Margin (Quarterly) | -35.31% |
| Earnings Yield | -11.35% |
| Normalized Earnings Yield | -11.71 |